

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 July 2025 (03.07.2025)



(10) International Publication Number
WO 2025/144717 A1

(51) International Patent Classification:

A61K 39/245 (2006.01) C12N 7/00 (2006.01)
A61P 31/20 (2006.01) C12N 15/86 (2006.01)
A61P 31/22 (2006.01)

(21) International Application Number:

PCT/US2024/061315

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/615,206 27 December 2023 (27.12.2023) US

(71) Applicant: **REPLICATE BIOSCIENCE, INC.** [US/US];
11558 Sorrento Valley Road, Suite 6, San Diego, California
92121 (US).

(72) Inventors: **ALIAHMAD, Parinaz**; c/o Replicate Bio-
science, Inc., 11558 Sorrento Valley Road, Suite 6,
San Diego, California 92121 (US). **MIYAKE-STONER,**

Shigeki Joseph; c/o Replicate Bioscience, Inc., 11558
Sorrento Valley Road, Suite 6, San Diego, California
92121 (US). **SPASOVA, Darina Svilenova**; c/o Repli-
cate Bioscience, Inc., 11558 Sorrento Valley Road, Suite
6, San Diego, California 92121 (US). **PICARDA, Gaëlle
Genevieve Alice**; c/o Replicate Bioscience, Inc., 11558 Sor-
rento Valley Road, Suite 6, San Diego, California 92121
(US).

(74) Agent: **DANG, David V.** et al.; Mintz Levin, One Financial
Center, Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSE AGAINST EPSTEIN-BARR VIRUSES

Exemplary design of a multigenic EBV vaccine




FIG. 1

(57) Abstract: The present disclosure relates to nucleic acids molecules, e.g., self-replicating RNA (srRNA) expressing antigenic determinant(s) derived from Epstein-Barr virus (EBV), recombinant cells and pharmaceutical compositions containing the same, as well as the use of such srRNA molecules, recombinant cells, and compositions for eliciting a pharmacodynamic effect in a subject. Also provided are methods for preventing and/or treating various health conditions associated with EBV infection.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))